Catalyst rival presents positive trial data

Catalyst Pharmaceutical Partners Inc.'s (Nasdaq: CPRX) rival Jacobus Pharmaceuticals presented positive data for a drug that is similar to one being developed by Catalyst sending the stock price tumbling 98 cents to close at $3.69.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.